Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
NEW YORK (Reuters Health) – Abatacept, an agent that modifies the costimulatory signal required for T-cell activation, does not increase malignancy rates in patients with rheumatoid arthritis (RA),…
NEW YORK (Reuters Health) – Methadone is a safe, effective first- or second-line treatment of cancer pain, even in outpatients, a retrospective study suggests. Concerns over its long…
NEW YORK (Reuters Health) – For men with hot flushes from androgen suppression for prostate cancer, medroxyprogesterone appears to be the best option for relief, according to a…
NEW YORK (Reuters Health) – New research suggests that high-dose vitamin D can be safely given to breast cancer patients with bone metastases, but it will not affect…
NEW YORK (Reuters Health) – In treating patients with metastatic melanoma, thalidomide plus temozolomide is no better than temozolomide or dacarbazine alone, according to a report in the…
NEW YORK (Reuters Health) – For a palpable breast mass with benign features on ultrasound, short-term follow-up is a reasonable alternative to immediate biopsy, particularly in a young…
NEW YORK (Reuters Health) – New research suggests that when noncalcified lung nodules are detected by computed tomography (CT), assessment of their volume and volume-doubling time with repeat…
NEW YORK (Reuters Health) – Adding cetuximab to standard chemotherapy for colorectal liver metastases often shrinks inoperable lesions enough to permit resection, according to a study released today…
NEW YORK (Reuters Health) – Treating HER-2 positive, metastatic breast cancer with trastuzumab significantly increased survival in a retrospective study, to the point were such women given the…
Robert Shorr, Ph.D, D.I.C, CEO, Cornerstone Pharmaceuticals, discusses how physicians can understand a new oncology drug, starting with knowing its safety limitations. He also explains the structure and…
